Diaceutics

DXRX · AIM · Health Care · mcap £173m · 195.0p 1 open situation →

Beta Briefing, track record and signals & risks are not ready for Diaceutics yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 FY 2026 revenue growth guidance 1 director buying

Open · 1

Upgrade / downgrade cycle

FY 2026 revenue growth guidance

On track; visibility 107% of consensus at 31 August

Next: conversion of pipeline into H2 revenue; FY26 outcome

22 Sep 2026 On track; visibility 107% of consensus at 31 August
29 Jul 2026 On track; H1 +22% cc, 91% visibility
26 May 2026 Reaffirmed as on track; Q1 up 15% constant currency
15 Jan 2026 25% FY 2026 revenue growth guided

Open the full view – chart and every step →

Closed · 1

Insider conviction1 director buying £16k in 1 buy · 31 Jan 2025 – 1 May 2025 −3%

Company filings. Not investment advice.